Results 121 to 130 of about 540,096 (367)

1337 Preclinical evaluation of STAR0602, a novel, first-in-class anti-TCR Vb targeted bispecific antibody with potent anti-tumor activity for PD-1 refractory solid tumors [PDF]

, 2022
Zhen Su, James L. Gulley, Jeffrey Schlom, Lillian L. Siu, Ryan J. Sullivan, E. John Wherry, Ke Liu, Renee N. Donahue, Madan Katraggada, Rajesh Chopra, Jacques Moisan, Jonathan C. Hsu, Yo-Ting Tsai   +12 more
openalex   +1 more source

Preoperative circulating tumor cells integrated with imaging analysis for prognostic evaluation in head and neck squamous cell carcinoma

Molecular Oncology, EarlyView.
Detecting circulating tumor cells (CTCs) in blood before surgery may help predict outcomes in patients with head and neck squamous cell carcinoma (HNSCC). Here, we show when combined with tumor size and lymph node involvement from routine imaging, CTC status identifies high‐risk patients with poorer survival—offering a simple, minimally invasive tool ...
Susanne Flach, Gizem Abaci, Tom Huberty, Axel Lechner, Lukas Käsmann, Jens Ricke, Sophia Stöcklein, Martin Canis, Philipp Baumeister, Marianna Alunni‐Fabbroni   +9 more
wiley   +1 more source

Strategies to drive chemotherapeutics to solid tumors: multifunctional nanoparticles from tailor-made block copolymers

, 2015
Nanotechnologies promise to drive a drug to tumors with improvement of activity profile, alleviation of side effects and increased patient survival.
QUAGLIA, FABIANA
core  

YES1 as a Possible Liquid Biopsy Biomarker in Lung Cancer

The Journal of Liquid Biopsy, 2023
N. Otegui, E. Redin, E. Janthus-Lewintre, S. Calabuig, M. Echepare, K. Valencia, S. Leon, M. Serrano, C. Camps, L. Montuenga, A. Calvo   +10 more
doaj   +1 more source

Supplemental Figure 2 from AKT1^low Quiescent Cancer Cells Promote Solid Tumor Growth [PDF]

, 2023
Cleidson P. Alves, Ipsita Dey‐Guha, Sheheryar Kabraji, Albert C. Yeh, Nilesh P. Talele, Xavier Solé, Joeeta Chowdhury, Mari Mino–Kenudson, Massimo Loda, Dennis C. Sgroi, Anne‐Lise Børresen‐Dale, Hege G. Russnes, Kenneth N. Ross, Sridhar Ramaswamy   +13 more
openalex   +1 more source

Screening and epitope characterization of Nidogen‐2‐specific nanobodies

FEBS Open Bio, EarlyView.
Camel immunization and phage display were employed to generate high‐affinity VHH nanobodies against Nidogen‐2. After library construction, biopanning, ELISA screening, sequencing, and recombinant expression, selected nanobodies were purified and characterized, leading to the preliminary exploration of a nanobody‐based sandwich ELISA for specific ...
Jianchuan Wen, Qianqian Cui, Zhongyun Lan, Yingjun Wang, Shuaiying Zhao, Wenxuan Feng, Yunfeng Liu, Qiting Huang, Dongna Zhang, Jianfeng Xu   +9 more
wiley   +1 more source

HER2DX ERBB2 mRNA score in first-line advanced HER2-positive breast cancer treated with chemotherapy, trastuzumab, and pertuzumab

npj Breast Cancer
In advanced HER2-positive breast cancer, the standard taxane-trastuzumab-pertuzumab (THP) regimen faces competition from new therapies, emphasizing the need for biomarkers to guide treatment.
Rodrigo Sánchez-Bayona, Olga Martínez-Sáez, Denys Romero-Romero, Elia Seguí, Esther Carcelero, Pablo Tolosa, Jesús Soberino, Manuel Alva, Tomás Pascual, Laura Lema, Isabel Garcia-Fructuoso, Maria Angeles Cobos-Fernandez, Maria Rey, Luis Manso, Angela Aguirre, Ainhoa Madariaga, Valeria Sirenko, Cristina González-Deza, Paula Blasco, Astrid Mayhua, Oleguer Castillo, Patricia Galván, Esther Sanfeliu, Guillermo Villacampa, Wesley Buckingham, Mercedes Marín-Aguilera, Laia Paré, Patricia Villagrasa, Charles M. Perou, Julia Maues, Fara Brasó-Maristany, Eva Ciruelos, Aleix Prat   +32 more
doaj   +1 more source

Supplementary Data from First-in-Human Trial of the Oral Ataxia Telangiectasia and RAD3-Related (ATR) Inhibitor BAY 1895344 in Patients with Advanced Solid Tumors [PDF]

, 2023
Timothy A. Yap, David S.P. Tan, Angelika Terbuch, Reece Caldwell, Christina Guo, Boon Cher Goh, Valerie Heong, Noor R. Md. Haris, Saira Bashir, Yvette Drew, David S. Hong, Funda Meric‐Bernstam, Gary Wilkinson, Joseph Hreiki, Antje M. Wengner, Friedhelm Bladt, Andreas Schlicker, Matthias Ludwig, Yinghui Zhou, Li Liu, Sonal Bordia, Ruth Plummer, Eleni Lagkadinou, Johann S. de Bono   +23 more
openalex   +1 more source

Proteasomal degradation of intracellularly expressed Amblyomin‐X limits suicide gene therapy potential in melanoma cells

FEBS Open Bio, EarlyView.
This study explores the feasibility of expressing the antitumoral protein Amblyomin‐X through a suicide gene therapy approach and investigates its intracellular fate after gene delivery. Although the gene is efficiently expressed, melanoma cells rapidly degrade the Amblyomin‐X protein via proteasome activity.
Victor Dal Posolo Cinel, Carlos DeOcesano Pereira, Aline Ramos Maia Lobba, Melissa Regina Fessel, Ana Marisa Chudzinski‐Tavassi   +4 more
wiley   +1 more source

Autoimmune Phenomena in Patients with Solid Tumors

, 2016
Introduction: Autoimmune disorders have been documented in solid tumors and malignant hematological disorders. They are very common and well studied in lymphomas which are associated with immune imbalance.
Tumbeva Dora Y., Beleva Elina A., Nenova Ivanka S., Rancheva Emilia L., Yaneva Marianna P., Valcheva Mariana Y., Grudeva-Popova Zhanet G.   +6 more
core   +1 more source